Body Mass Index (BMI) and Its Influence on the Cardiovascular and Operative Risk Profile in Coronary Artery Bypass Grafting Patients: Impact of Inflammation and Leptin

Katja Buschmann,1 Julius Wrobel,1 Ryan Chaban,1 Romina Rösch,1 Ahmed Ghazy,1 Alina Hanf,2 Katrin Schäfer,2,3 Andreas Daiber1,2,3 Andreas Beiras-Fernandez,1 and Christian Friedrich Vahl1

1Department of Cardiothoracic and Vascular Surgery, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
2Center for Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany
3German Center for Cardiovascular Research (DZHK), partner site Rhine-Main, Mainz, Germany

Correspondence should be addressed to Katja Buschmann; katja.buschmann@unimedizin-mainz.de

Received 7 April 2020; Revised 29 May 2020; Accepted 3 June 2020; Published 24 June 2020

Guest Editor: Karolina Szewczyk-Golec

Copyright © 2020 Katja Buschmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Obesity is related to coronary artery disease (CAD) and worse outcomes in coronary artery bypass graft (CABG) patients. Adipose tissue itself is an endocrine organ that secretes many humoral mediators, such as adipokines, which can induce or reduce inflammation and oxidative stress. Objectives. We investigate the relationship between the body mass index (BMI), inflammation, and oxidative stress by measuring serum levels of leptin, interleukin-6, and 3-nitrotyrosine in CABG patients and correlate their levels to the cardiovascular and operative risk profiles. Methods and Results. 45 men (<75 years) with a median BMI of 29 (21-51) kg/m², who were diagnosed with CAD and scheduled for elective CABG, were included after applying the following exclusion criteria: prior myocardial infarction, reoperation, female gender, and smoking. Patients’ blood samples were taken preoperatively. Several markers were measured. We found significant correlations between leptin and BMI (p < 0.0001) as well as between leptin and 3-nitrotyrosine (p = 0.006). Interleukin-6 was correlated with C-reactive protein (p < 0.0001) and with the incidence of insulin-dependent diabetes mellitus (p = 0.036), arterial hypertension (p = 0.044), reduced left ventricular function (p = 0.003), and severe coronary calcification (p = 0.015). It was also associated with significantly longer extracorporeal bypass time (p = 0.009). Postoperative deep sternal wound infections could be predicted by a higher BMI (p = 0.003) and leptin level (p = 0.001). Conclusions. There seems to be a correlation between inflammatory processes and cardiovascular morbidity in our cohort. Further, the incidence of deep sternal wound infections is related to a higher BMI and leptin serum level.

1. Introduction

Adiposity is well-known as a cardiovascular risk factor. Obese coronary artery bypass graft (CABG) patients are associated with higher postoperative morbidity and worse long-term survival [1]. Nevertheless, the body mass index (BMI) itself does not play a role in preoperative risk adjustment scores for cardiac surgery so far [2]. In a former experimental study, we could prove a correlation of BMI with a negative inotropic effect in an isolated human myocardium [3]. The adipose tissue itself is the largest endocrine organ of the human body and secretes more than 150 adipokines with mostly proinflammatory and cardiovascular potent mediation [4–8].

Clinical studies in humans showed that obesity—defined by raised BMI—is associated with elevated serum levels of the
2. Materials and Methods

2.1. Patients. This study was approved by the Institutional Review Board (processing number 837.051.15 (9819), 23 March 2015). A total of 45 consecutive elective isolated CABG patients with CAD and a median BMI of 29 [21–51] kg/m², male gender, and an age between 50 and 75 years (67 ± 8.4 years) were included. Exclusion criteria were prior myocardial infarction, reoperation, female gender, and smoking. Figure 1 shows the timing of the screening visit, the evaluation and documentation of preoperative characteristics, preoperative blood markers, and the final documentation of intraoperative and intensive care unit (ICU) data as well as the discharge data for the final recording of deep sternal wound infection (DSWI), as a postoperative complication. The observation period ended with the discharge of the patient. We interviewed the study patients for their age and the presence of cardiovascular risk factors as insulin-dependent diabetes mellitus (IDDM), familiar disposition, and arterial hypertension (AHT). Further comorbidities such as renal dysfunction, assessed by the creatinine serum level, and left ventricular ejection fraction (LVEF) were recorded. Blood samples were obtained simultaneously with the regular clinical blood sampling at administration, usually 24 hours before surgery. We measured leptin, IL-6, CRP, leukocytes, and 3-nitrotyrosine (3-NT). The duration of extracorporeal circulation (ECC) is relevant for postoperative outcome and therefore reported as well as the diagnosis of a severe coronary calcification, assessed by the cardiac surgeon in his operation report. The time on respirator and stay length on ICU were documented. Clinical assessments and documentations were used for the query of DSWI, a therapy relevant psychosyndrome and death.

2.2. Blood Biomarkers. Patients’ blood samples were taken preoperatively each with 3 serum pipes. IL-6, CRP, and leukocytes were measured by the intern laboratory medicine. The other samples were frozen and collected for leptin enzyme-linked immunosorbent assay (ELISA) and oxidative stress level determination. Serum leptin levels were determined using a commercially available Human Leptin QuantiKine ELISA Kit (R&D Systems), following the instructions of the manufacturer.

2.3. 3-Nitrotyrosine Levels (3-NT). Levels of 3-NT and 8-isoprostane, as markers of oxidative stress, were determined in human serum using a commercial ELISA kit (human immunoassay, 3-NT: #CSB-E14324h, Cusabio, Wuhan, Hubei Province 430206, China; 8-isoprostane: #MBS109360, San Diego, CA, USA) following the instructions of the vendor and previously [17]. Protein tyrosine nitration was also determined by dot blot analysis using a specific antibody for 3-NT (Millipore 05-233 Mouse mAb, 1: 1000 in PBS/5% Milk) [17, 18]. Brieﬂy, 100 μl (0.5 μg/μl protein based on Bradford analysis) of the ethylenediaminetetraacetic acid (EDTA) plasma
was transferred to a Protran BA85 (0.45 μm) nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) using a Minifold I vacuum Dot-Blot system (Schleicher & Schuell, Dassel, Germany). Each slot was washed twice with 200 μl phosphate-buffered saline (PBS) before and after protein transfer. The membrane was dried for 60 min at 60°C. Positive bands were detected by enhanced chemiluminescence after incubation with peroxidase-coupled anti-mouse or rabbit secondary antibodies for 3-NT-positive proteins or transferrin, respectively (goat-anti-mouse-peroxidase-labeled and goat-anti-rabbit-peroxidase-labeled, 1:10,000) (Vector Laboratories, CA, USA). All incubation and washing steps were performed according to the manufacturer’s instructions. Densitometric quantification of the dots was performed using the SuperSignal-enhanced chemiluminescence kit from Thermo Scientific. The densitometric 3-NT signals were normalized to either Ponceau S staining or to the densitometric signals of the serum loading control transferrin (anti-transferrin antibody (Thermo Fisher PA3-913); rabbit pAb, 1:5,000 in PBS-T/5% BSA) staining (rel. IOD, % of control).

2.4. Statistical Analysis. Statistical description and analyses were performed using IBM SPSS 23 (IBM, USA). Quantitative variables were expressed as the mean ± standard deviation if they were normally distributed (skewness between -1 and 1) and as median with range if they were not normally distributed (skewness < -1 and>1). For nonparametric data, the Mann–Whitney U or the exact Fisher test were used; for parametric data Student’s t-test. Linear regression was used for the assessment of correlation between metric parameters. An alpha-value of 0.05 was chosen for significance. The cut-off values were determined within an ROC analysis. As cut-off, the values with the smallest Euclidian distance to the upper left of the plot were taken.

3. Results

3.1. Blood Markers and Hospitalization Data. BMI and all measured blood markers showed a wide variation: BMI 29 (21-51) kg/m², leptin 9.157 (1.594-87.984) ng/mL, IL-6 16.5 (2-79) ng/L, CRP 5.3 (0.29-291) mg/L, leucocytes 8.2 (4.46-24.3) cells/nL, and 3-NT 53.24 (21.26-187.20) (rel. IOD, % of control). Time on ECC was 24.3) cells/nL, and 3-NT 53.24 (21.26-187.20) (rel. IOD, % of control). Time on ECC was 71.14 ± 20.77 minutes. Severe coronary calcifications were assessed in 21 CABG operations. The postoperative time on respirator was 10 (1-420) hours and stay on ICU was 2.54 ± 3.69 days. With the discharge of the patient to home or to rehabilitation 5 cases of DSWI, no psycho syndrome and no death were recorded.

3.2. Inflammation Markers and Preoperative Risk Profile. Parameters of inflammation showed a significant correlation as CRP was significantly correlated with IL-6 (p < 0.0001, R² = 0.3) and leucocytes (p = 0.003, R² = 0.186) (Figure 2). On the other hand, IL-6 serum levels were not affected by the BMI (p = 0.821, R² = 0.001) and did not correlate with serum leptin levels (p = 0.608, R² = 0.007). Leptin was significantly correlated with BMI (p < 0.0001, R² = 0.6) (Figure 3) and also with the oxidative stress marker 3-NT (p = 0.0109, R² = 0.1628 or p = 0.0062, R² = 0.1857, depending on the normalization method) (Figure 4). In a pilot experiment, we confirmed that patients with high leptin levels have higher oxidative stress parameters (3-NT and 8-isoprostane). The distribution pattern also varied to some extent in dependence of the normalization method, but the overall trend was reproducible in both measurements. 3-NT was not significantly correlated with IL-6 (p = 0.7169, R² = 0.0038) (Figure 5).

Preoperative left ventricular ejection fraction was inversely correlated with IL-6 (p = 0.003, R² = 0.202), CRP (p = 0.005, R² = 0.171), and leucocytes (p = 0.005, R² = 0.170), whereas patients with IDDM showed significantly higher level of IL-6 (p = 0.036) as well as patients with AHT (p = 0.044) (Figure 6). Furthermore, preoperative creatinine was proportional correlating with leptin (p = 0.001, R² = 0.223) and also significantly higher in patients with positive troponin (p = 0.003). Patients’ age showed no statistical relation to IDDM, AHT, or familiar disposition.

3.3. Inflammation Markers and Coronary Sclerosis. Severe coronary sclerosis was assessed in 21 patients; these patients did not show a significantly higher blood level of leucocytes,
but were outstanding with significantly higher blood levels of IL-6 ($p = 0.015$) (Figure 7). Patients’ age, creatinine value, and LVEF were neither significant for the CVR profile nor for the severity of coronary calcification (Table 1). Patients with reduced LVEF did show the trend of a higher rate of severe coronary calcification ($p = 0.09$, Table 1) In addition to this, patients with severe coronary sclerosis had a significantly higher rate of IDDM ($p = 0.031$), and bypass grafting operation demanded significantly longer time on ECC (63.57 minutes versus 79.85 minutes, $p = 0.009$). The time on respirator was correlated with BMI ($p = 0.042$, $R^2 = 0.104$) and CRP ($p = 0.024$, $R^2 = 0.127$) and significantly longer in patients with IDDM ($p = 0.004$). Furthermore, patients with IDDM did show a prolonged stay on ICU ($p = 0.008$).

There were 5 cases of DSWI. Reliable DSWI markers were leptin ($p = 0.001$) and BMI ($p = 0.003$) (Figure 8). Patients with DSWI were significantly more often diabetic patients ($p = 0.021$) but did neither exceed in time on respirator nor on intensive care unit.

3.4. Analysis of Cut-Off Values. The inflammatory marker IL-6 delivers cut-off values for the cardiovascular and operative risk profile by significant correlation with IDDM, AHT, and severe coronary calcification whereas leptin and BMI are predictive for DSWI (Table 2).

4. Discussion

4.1. Main Findings and Clinical Relevance. This study investigated the association of the inflammatory marker IL-6 with
the cardiovascular and operative risk profile of CABG patients. We found that IL-6 is associated with the cardiovascular (IDDM and AHT) as well as for the operative risk profile (inversely correlated with LVEF and severe coronary calcification). This finding is in accordance with the reported low-grade inflammatory phenotype of IDDM and AHT [19]. The clinical importance of IDDM and AHT is further supported by large epidemiological studies ranking them among the leading cardiovascular risk factors and causes of premature death at the global level [20]. AHT and its correlation with inflammation markers (CRP or IL-6) have been also described in literature [21]. Patients with reduced LVEF show the trend to have more often a severe coronary sclerosis. In the present study, the inflammation markers IL-6 and CRP and the number of leucocytes were significantly correlated. Moreover, we demonstrate a correlation between leptin and BMI and that both parameters are associated with DSWI as an operative complication risk.

**Figure 6:** IL-6 levels in patients with (a) AHT (n = 39) and (b) IDDM (n = 7) compared to IL-6 levels in patients without arterial hypertension (no AHT/control (a), n = 6) and without IDDM (no IDDM/control (b), n = 38). IL-6 levels were significantly higher in patients with AHT (3.5 ± 0.7 vs 11.9 ± 2.6 ng/l) and with IDDM (10.3 ± 2.6 vs 13.2 ± 2.3 ng/l). Data are mean ± SEM.

**Figure 7:** IL-6 levels (a) and leucocytes (b) compared in patients with intraoperative status of severe coronary calcification (sclerosis, black) or normal coronary sclerosis (control, grey). Patients with severe coronary calcification had significantly higher levels of IL-6 (6.1 ± 1.1 vs 15.8 ± 4.4 ng/l), whereas leucocytes were only increased by trend (7.7 ± 0.4 vs 10.2 ± 1.1 cells/ng, p = 0.085). Data are mean ± SEM, n = 21–24 patients.

**Table 1:** Patients’ comorbidities (age, creatinine, and left ventricular function) are not significantly influencing the cardiovascular risk profile (IDDM, familial disposition, and arterial hypertension) or significantly correlating with the intraoperative finding of a severe coronary calcification. However, there is a significant relation between the value of the left ventricular function (LVEF %) and severe coronary calcification.

|                     | Insulin-dependent DM [0: n = 38, 1: n = 7] | Familiar disposition [0: n = 33, 1: n = 12] | Arterial hypertension [0: n = 6, 1: n = 39] | Severe coronary calcification [0: n = 24, 1: n = 21] |
|---------------------|-------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Age (years)         | p = 0.58                                  | p = 0.97                                    | p = 0.66                                    | p = 0.89                                    |
| Creatinine (mg/dL)  | p = 0.95                                  | p = 0.60                                    | p = 0.79                                    | p = 0.82                                    |
| LVEF (%)            | p = 0.87                                  | p = 0.38                                    | p = 0.71                                    | p = 0.09                                    |
With a median 9.2 ng/mL [0.7-90.6 ng/mL] in patients with insulin-dependent diabetes as a cardiovascular risk factor, the intraoperatively due to insulin resistance in diabetic and adipose patients may contribute to a rather reduced leptin e-
cific, and thereby increasing operative risk. Also the leucocytes were significantly correlated with the status of severe coronary calcification in the present study, similar to the inflammation marker IL-6. Although, previous data do not support a significant correlation of coronary calcification and CRP levels in CABG patients, a subgroup analysis in statin-free patients found a clear correlation [22]. Another recent study has proven the association between fibrinogen level, an acute phase protein, and a parameter of inflammation, the severity of coronary stenosis [23]. CRP is significantly correlated with the time on respirator [24]. Thus, elective CABG patients with preoperatively raised CRP values should firstly be searched for an infective pulmonary focus and optionally be treated with antibiotic therapy until surgery can be planned. Although higher preoperative CRP levels are mostly related to infections [25], also other conditions such as schizophrenia, cardiogenic shock, and autoimmune conditions, including rheumatoid arthritis, lupus, and certain types of inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis, may be associated with increased CRP levels.

4.2. CABG Surgery and Inflammation. Severe coronary calcification (reported by the surgeon itself) is accompanied by significantly longer time on ECC and thereby increasing operative risk. Also the leucocytes were significantly correlated with the status of severe coronary calcification in the present study, similar to the inflammation marker IL-6. Although, previous data do not support a significant correlation of coronary calcification and CRP levels in CABG patients, a subgroup analysis in statin-free patients found a clear correlation [22]. Another recent study has proven the association between fibrinogen level, an acute phase protein, and a parameter of inflammation, the severity of coronary stenosis [23]. CRP is significantly correlated with the time on respirator [24]. Thus, elective CABG patients with preoperatively raised CRP values should firstly be searched for an infective pulmonary focus and optionally be treated with antibiotic therapy until surgery can be planned. Although higher preoperative CRP levels are mostly related to infections [25], also other conditions such as schizophrenia, cardiogenic shock, and autoimmune conditions, including rheumatoid arthritis, lupus, and certain types of inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis, may be associated with increased CRP levels.

4.3. CABG Surgery and Leptin. Our determination of leptin in this cohort of patients is completely coherent with the literature. Considine et al. describe leptin levels in obese with 31.3 ± 24.1 ng/mL and about 7.5 ± 9.3 ng/mL in normal-weighted humans [9], and Wolk et al. reported leptin levels with median 9.2 ng/mL [0.7-90.6 ng/mL] in patients with established CAD [12]. Both are similar to our results with median 9.157 (1.594-87.984) ng/mL. Furthermore, Wolk et al. reported that the leptin level is independent of other risk factors, e.g., lipid status and CRP. In this clinical study, the systemic leptin level was also not correlated with markers of inflammation. This can be caused by many other relevant effects of pro- and anti-inflammatory adipokines. Furthermore, we observed increased oxidative stress in patients with systemic higher levels of leptin. This can be explained by the fact that oxidative stress reduces the production of beneficial, anti-inflammatory adipokines [26]. In line with this notion, oxidative stress negatively affects the collagen turnover and supports the synthesis of collagen, for example, in the heart, resulting in worse LVEF by the remodeling process [27]. In a former experimental study, we found also signs of fibrotic remodeling in septic/inflammatory cardiomyopathy [28]. A more recent study proposed the leptin/adiponectin ratio as another parameter of prognostic importance besides markers of inflammation [29].

4.4. CABG Surgery and BMI. In our study, leptin is significantly correlated with the BMI. However, there are clear difficulties reported for the leptin level dependence on BMI [30]. In addition, the development of leptin resistance due to insulin resistance in diabetic and adipose patients may contribute to a rather reduced leptin effect [30, 31]. Regarding the here established significant correlation of BMI and leptin, it should be stressed that the preoperative BMI in CABG patients was associated with DSWI, a major complication in CABG surgery, and thereby may confer

| Cut-off values | Insulin-dependent DM | Arterial hypertension | Severe coronary calcification | Deep sternal wound infection |
|---------------|----------------------|-----------------------|-----------------------------|----------------------------|
| IL-6 (ng/L)   | 15.5                 | 6.5                   | 12.5                        | 37.0                       |
| BMI (kg/m²)   |                        |                       |                             |                            |
| Leptin (ng/mL)|                        |                       |                             |                            |

Figure 8: BMI (a) and leptin levels (b) in patients with deep sternal wound infection (black, DSWI, n = 5) versus the control (grey) group (n = 40). Patients with DSWI had significantly higher BMI (29.4 ± 0.9 vs 40.0 ± 3.1 kg/m²) and significantly raised levels of leptin (12.2 ± 2.2 vs 27.7 ± 5 ng/l). Data are mean ± SEM.
some prognostic value to BMI as well as leptin levels (BMI > 37 kg/m² cut-off, Table 2). This is further supported by the significant correlation of leptin with the preoperative creatinine levels in our patient collective. This relation is also described by others [21, 31]. Also, previous studies reported on a higher risk for major complications among CABG patients with increasing BMI [32, 33].

4.5. Leptin, Inflammation, Arterial Hypertension, and Diabetes Mellitus. Tsai et al. showed a correlation between AHT and leptin predicting arterial stiffness in hypertensive patients [21]. In our results, we could not show any correlation between leptin and AHT. One explanation could be the bias of IDDM—at least seven patients in our study collective showing decreased leptin levels [30, 31]. Nevertheless, both of our study groups—with or without IDDM—show median leptin levels with 9.2/9.1 ng/mL. There is no effect of age (Table 1) upon the severity of coronary calcification. But patients with a preoperatively reduced LVEF showed the trend of a higher rate of severe coronary calcification—accompanied with and presumably caused by raised inflammation (marker IL-6). Nevertheless, inflammation markers in the blood seem to have more influence resulting in cardiovascular damage like AHT and coronary calcification.

The significance of the preoperative creatinine level was neither demonstrated in our study nor in another recent longitudinal study [34]. In our work, there was a significantly higher rate of severe coronary calcification in patients with IDDM. A recent study with the optical coronary tomography method [35] could exclude any impact of type 2 diabetes mellitus on coronary calcification but has proven the burden of a plaque rupture in type 2 diabetes mellitus. The definition of type 2 diabetes mellitus was Hba1c > 6.5% or intake of oral antidiabetic drugs. In our study, the criteria were stronger with the insulin-dependency. Thus, both different results are not comparable.

One explanation could be that there are pro- and anti-inflammatory adipokines that, depending on their expression profile, promote or suppress inflammation. In this study, we did only measure the proinflammatory leptin without measurement of an antagonist, e.g., the anti-inflammatory adiponectin. Instead, we concentrated on the consequences of inflammation by measurement of the oxidative stress marker 3-NT and its correlation with IL-6. To our surprise, we could not show a positive correlation between IL-6 and oxidative stress (Figure 5).

4.6. Limitations of the Study. A major limitation of our study is the small cohort size, thus limiting the power of our findings and resulting in small effect sizes. Previous studies were based on several hundreds of individuals, e.g., the investigation of risk factors for surgical wound infections and postoperative bacteremia for patients undergoing CABG surgery (n = 693) [36]. In addition, our observation period was quite short and ends with the discharge from hospital. Similar studies used longer follow-up periods of up to five years, e.g., investigation of impact of BMI and the associated biomarkers on clinical outcomes after CABG (n = 234) [32].

5. Conclusion

In our study, neither the BMI and nor the leptin level are as relevant as the systemic inflammation markers that are probably responsible for the worse prognosis and high cardiovascular event rate in obese CABG patients. Our observations are in good accordance with meta-analysis reporting pre- and perioperative inflammation to be major determinants of prognosis among CABG patients [37]. This may also explain why modern antidiabetic drugs with clearly characterized anti-inflammatory properties show beneficial effects on prognosis among CABG patients. Examples are the therapy with a sodium glucose cotransporter 2 inhibitor [38], glucagon-like peptide-1 [39], statins [40, 41], or even a specific anti-inflammatory, monoclonal-based drug [42].

Abbreviations

- [0/1]: No/yes
- AHT: Arterial hypertension
- BMI: Body mass index (body weight (kilogram)/body height (m²)
- CABG: Coronary artery bypass graft
- CAD: Coronary artery disease
- CRP: C-reactive protein
- CVR: Cardiovascular risk
- ECC: Extracorporeal circulation
- ELISA: Enzyme-linked immunosorbent assay
- ICU: Intensive care unit
- IDDM: Insulin-dependent diabetes mellitus (type II)
- DSWI: Deep sternal wound infection
- IL-6: Interleukin 6
- LVEF: Left ventricular ejection fraction
- 3-NT: 3-nitrotyrosine
- SD (in Results): Standard deviation
- SEM (Figures 4-7): Standard error of the mean.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflict of interest.

Authors’ Contributions

K.B., R.C., A.B.-F., and C.F.V. conceived and designed research; J.W., A.G., R.R., A.H., and K.S. carried out experiments; K.B., R.C., A.H., K.S., and A.D. performed data analysis; K.B. and A.D. drafted the manuscript. R.C. and C.F.V. made critical contribution to the discussion. K.B., A.D., R.C., and C.F.V. revised the manuscript. All authors read and approved the final manuscript.
Acknowledgments

A.D. was continuously supported by the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. A.H. held a stipend from the International PhD Program on the “Dynamics of Gene Regulation, Epigenetics and DNA Damage Response” from the Institute of Molecular Biology gGmbH (Mainz, Germany) funded by the Boehringer Ingelheim Foundation.

References

[1] R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah, "Effects of obesity and small body size on operative and long-term outcomes of coronary artery bypass surgery: a propensity-matched analysis," The Annals of Thoracic Surgery, vol. 79, no. 6, pp. 1976–1986, 2005.

[2] F. Roques, P. Michel, A. R. Goldstone, and S. A. M. Nashef, "The logistic EuroSCORE," European Heart Journal, vol. 24, no. 9, pp. 881-882, 2003.

[3] K. Denk, J. Albers, N. Kayhan et al., "Evidence for a negative inotropic effect of obesity in human myocardium?" European Journal of Cardio-Thoracic Surgery, vol. 36, no. 2, pp. 300–305, 2009.

[4] V. Lamounier-Zepter, M. Ehrhart-Bornstein, P. Karcewski, H. Haase, S. R. Bornstein, and I. Morano, "Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity," The FASEB Journal, vol. 20, no. 10, pp. 1653–1659, 2006.

[5] M. Gnaciński, S. Malgorzewicz, M. Stojek, W. Łysiak-Szydlowska, and K. Sworczak, "Role of adipokines in complications related to obesity: a review," Advances in Medical Sciences, vol. 54, no. 2, pp. 150–157, 2009.

[6] A. Stołkowa, "Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity," Endocrine Regulations, vol. 43, pp. 157–168, 2009.

[7] E. Maury and S. M. Brichard, "Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome," Molecular and Cellular Endocrinology, vol. 314, no. 1, pp. 1–16, 2010.

[8] S. Dhein, "Fat and the heart: a more and more complex interplay," The Thoracic and Cardiovascular Surgeon, vol. 62, no. 7, pp. 543–546, 2014.

[9] R. V. Considine, M. K. Sinha, M. L. Heiman et al., "Serum immunoreactive-leptin concentrations in normal-weight and obese humans," The New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996.

[10] A. Qasim, N. N. Mehta, M. G. Tadesse et al., "Adipokines, insulin resistance, and coronary artery calcification," Journal of the American College of Cardiology, vol. 52, no. 3, pp. 231–236, 2008.

[11] S. G. Wannamethee, J. Tchernova, P. Whincup et al., "Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease," Atherosclerosis, vol. 191, no. 2, pp. 418–426, 2007.

[12] R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, B. D. Johnson, and V. K. Somers, "Plasma leptin and prognosis in patients with established coronary atherosclerosis," Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1819–1824, 2004.

[13] N. Sattar, G. Wannamethee, N. Sarwar et al., "Leptin and coronary heart disease: prospective study and systematic review," Journal of the American College of Cardiology, vol. 53, no. 2, pp. 167–175, 2009.

[14] K. Isozumi, "Obesity as a risk factor for cerebrovascular disease," The Keio Journal of Medicine, vol. 53, no. 1, pp. 7–11, 2004.

[15] P. C. Schulze and J. Kratsch, "Leptin as a new diagnostic tool in chronic heart failure," Clinica Chimica Acta, vol. 362, no. 1–2, pp. 1–11, 2005.

[16] V. Abella, M. Scotece, J. Conde et al., "Leptin in the interplay of inflammation, metabolism and immune system disorders," Nature Reviews Rheumatology, vol. 13, no. 2, pp. 100–109, 2017.

[17] T. Münzel, A. Daiber, S. Steven et al., "Effects of noise on vascular function, oxidative stress, and inflammation: mechanistic insight from studies in mice," European Heart Journal, vol. 38, no. 37, pp. 2838–2849, 2017.

[18] S. Kröller-Schön, A. Daiber, S. Steven et al., "Crucial role for Nox2 and sleep deprivation in aircraft noise-induced vascular and cerebral oxidative stress, inflammation, and gene regulation," European Heart Journal, vol. 39, no. 38, pp. 3528–3539, 2018.

[19] S. Steven, K. Frenis, M. Oelze et al., "Vascular inflammation and oxidative stress: major triggers for cardiovascular disease," Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 7092151, 26 pages, 2019.

[20] A. J. Cohen, M. Brauer, R. Burnett et al., "Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015," The Lancet, vol. 389, no. 10082, pp. 1907–1918, 2017.

[21] J. P. Tsai, B. G. Hsu, C. J. Lee, Y. H. Hsieh, Y. C. Chen, and J. H. Wang, "Serum leptin is a predictor for central arterial stiffness in hypertensive patients," Nephrology (Carlton), vol. 22, no. 10, pp. 783–789, 2017.

[22] A. Hosseinzabeh, A. Mohebbi, and A. Almasi, "C-reactive protein and coronary calcium score association in coronary artery disease," Cardioiology Journal, vol. 15, no. 5, pp. 431–436, 2008.

[23] X. Y. Gao, B. Y. Zhou, M. Z. Zhang et al., "Serum leptin and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old," Oncotarget, vol. 8, no. 46, pp. 81361–81368, 2017.

[24] S. M. A. Lobo, F. R. M. Lobo, D. P. Bota et al., "C-Reactive Protein Levels Correlate With Mortality and Organ Failure in Critically Ill Patients," Chest, vol. 123, no. 6, pp. 2043–2049, 2003.

[25] A. Landry, P. Docherty, S. Ouellette, and L. J. Cartier, "Causation and outcomes of markedly elevated C-reactive protein levels," Canadian Family Physician, vol. 63, pp. e316–e323, 2017.

[26] N. Netzer, H. Gatterer, M. Faulhaber, M. Bartscher, S. Pramsohler, and D. Pest, "Hypoxia, oxidative stress and fat," Biomolecules, vol. 5, no. 2, pp. 1143–1150, 2015.

[27] E. Martinez-Martinez, R. Jurado-López, M. Valero-Muñoz et al., "Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress," Journal of Hypertension, vol. 32, no. 5, pp. 1104–1114, 2014.

[28] K. Buschmann, R. Chaban, A. L. Emrich et al., "Septic cardiomyopathy: evidence for a reduced force-generating capacity of..."
human atrial myocardium in acute infective endocarditis,” *Innovative Surgical Sciences*, vol. 2, no. 2, pp. 81–87, 2017.

[29] C. Sardu, N. D’Onofrio, M. Torella et al., “Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin,” *Cardiovascular Diabetology*, vol. 18, no. 1, p. 126, 2019.

[30] I. A. Ku, R. Farzaneh-Far, E. Vittinghoff, M. H. Zhang, B. Na, and M. A. Whooley, “Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study,” *Atherosclerosis*, vol. 217, no. 2, pp. 503–508, 2011.

[31] X. Gu, Z. Chen, and I. El Bayoumy, “Serum leptin levels in obese women with and without type 2 diabetes mellitus,” *Minerva Endocrinologica*, vol. 39, no. 3, pp. 223–229, 2014.

[32] S. H. Sung, T. C. Wu, C. H. Huang, S. J. Lin, and J. W. Chen, “Prognostic impact of body mass index in patients undergoing coronary artery bypass surgery,” *Heart*, vol. 97, no. 8, pp. 648–654, 2011.

[33] F. D. Ramirez, B. Hibbert, T. Simard et al., “Clinical outcomes among patients with extreme obesity undergoing elective coronary revascularization: Evaluation of major complications in contemporary practice,” *International Journal of Cardiology*, vol. 186, pp. 266–272, 2015.

[34] C. Sub-Chiou, R. M. Moysés, M. S. Bittencourt, I. M. Bensenor, and P. A. Lotufo, “Chronic kidney disease and coronary artery calcification in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil),” *Clinical Cardiology*, vol. 40, no. 12, pp. 1309–1315, 2017.

[35] A. Milzi, M. Burgmaier, K. Burgmaier, M. Hellmich, N. Marx, and S. Reith, “Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study,” *Cardiovascular Diabetology*, vol. 16, no. 1, p. 152, 2017.

[36] D. W. Spelman, P. Russo, G. Harrington et al., “Risk factors for surgical wound infection and bacteraemia following coronary artery bypass surgery,” *The Australian and New Zealand Journal of Surgery*, vol. 70, no. 1, pp. 47–51, 2000.

[37] A. Weymann, A.-F. Popov, A. Sabashnikov et al., “Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis,” *KardioLOGIA Polska*, vol. 76, pp. 440–451, 2017.

[38] S. Verma, C. D. Mazer, D. Fitchett et al., “Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial,” *Diabetologia*, vol. 61, no. 8, pp. 1712–1723, 2018.

[39] G. G. Sokos, H. Bolukoglu, J. German et al., “Effect of glucagon-like peptide-1 (GLP-1) on glyemic control and left ventricular function in patients undergoing coronary artery bypass grafting,” *The American Journal of Cardiology*, vol. 100, no. 5, pp. 824–829, 2007.

[40] I. Singh, S. Rajagopalan, A. Srinivasan et al., “Preoperative statin therapy is associated with lower requirement of renal replacement therapy in patients undergoing cardiac surgery: a meta-analysis of observational studies,” *Interactive Cardiovascular and Thoracic Surgery*, vol. 17, no. 2, pp. 345–352, 2013.

[41] C. N. Bang, A. M. Greve, J. Abdulla, L. Kober, G. H. Gislason, and K. Wachtell, “The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis,” *International Journal of Cardiology*, vol. 167, no. 3, pp. 624–630, 2013.

[42] J. A. Patel and S. B. Ghatak, “Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review,” *Recent Patents on Cardiovascular Drug Discovery*, vol. 3, no. 2, pp. 145–152, 2008.